GSK-3 inhibition: Achieving moderate efficacy with high selectivity

Biochimica et Biophysica Acta - Proteins and Proteomics

Volumn 1834, Issue 7, 2013, Pages 1410-1414

  Avrahami, Limor ^a   Licht Murava, Avital ^a   Eisenstein, Miriam ^b   Eldar Finkelman, Hagit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Alzheimer's disease; CNS disorders; Drug design; GSK 3 inhibitors; L803 mts

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; PEPTIDE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BIPOLAR DISORDER; BRAIN ISCHEMIA; COMPETITIVE INHIBITION; ENZYME INHIBITION; EPILEPSY; FRAGILE X SYNDROME; HUMAN; HUNTINGTON CHOREA; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SPINAL MUSCULAR ATROPHY; SPINOCEREBELLAR DEGENERATION;

GLYCOGEN SYNTHASE KINASE 3; HUMANS; MENTAL DISORDERS; MODELS, MOLECULAR; NEURODEGENERATIVE DISEASES; OLIGOPEPTIDES; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY;

EID: 84878874968     PISSN: 15709639     EISSN: 18781454     Source Type: Journal    
DOI: 10.1016/j.bbapap.2013.01.016     Document Type: Review

References (91)

1. P.S. Klein, and D.A. Melton A molecular mechanism for the effect of lithium on development Proc. Natl. Acad. Sci. U. S. A. 93 1996 8455 8459 (Pubitemid 26269579)
2. V. Stambolic, L. Ruel, and J.R. Woodgett Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells Curr. Biol. 6 1996 1664 1668 (Pubitemid 27050234)
3. R. Gomez-Sintes, F. Hernandez, J.J. Lucas, and J. Avila GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration Front. Mol. Neurosci. 4 2011 45
4. C. Hooper, R. Killick, and S. Lovestone The GSK3 hypothesis of Alzheimer's disease J. Neurochem. 104 2008 1433 1439 (Pubitemid 351316776)
5. D. Terwel, D. Muyllaert, I. Dewachter, P. Borghgraef, S. Croes, H. Devijver, and F. Van Leuven Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice Am. J. Pathol. 172 2008 786 798 (Pubitemid 351354550)
6. R.S. Jope, C.J. Yuskaitis, and E. Beurel Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics Neurochem. Res. 32 2007 577 595 (Pubitemid 46481289)
7. H.C. Huang, and P.S. Klein Multiple roles for glycogen synthase kinase-3 as a drug target in Alzheimer's disease Curr. Drug Targets 7 2006 1389 1397 (Pubitemid 44718299)
8. V. Palomo, D.I. Perez, C. Gil, and A. Martinez The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy Curr. Med. Chem. 18 2011 3028 3034
9. K. Spittaels, C. Van den Haute, J. Van Dorpe, D. Terwel, K. Vandezande, R. Lasrado, K. Bruynseels, M. Irizarry, M. Verhoye, J. Van Lint, J.R. Vandenheede, D. Ashton, M. Mercken, R. Loos, B. Hyman, A. Van der Linden, H. Geerts, and F. Van Leuven Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice Neuroscience 113 2002 797 808 (Pubitemid 35245250)
10. F. Hernandez, J. Borrell, C. Guaza, J. Avila, and J.J. Lucas Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments J. Neurochem. 83 2002 1529 1533 (Pubitemid 35477491)
11. J. Prickaerts, D. Moechars, K. Cryns, I. Lenaerts, H. van Craenendonck, I. Goris, G. Daneels, J.A. Bouwknecht, and T. Steckler Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania J. Neurosci. 26 2006 9022 9029 (Pubitemid 44319393)
12. A. Polter, E. Beurel, S. Yang, R. Garner, L. Song, C.A. Miller, J.D. Sweatt, L. McMahon, A.A. Bartolucci, X. Li, and R.S. Jope Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances Neuropsychopharmacology 35 2010 1761 1774
13. J.J. Lucas, F. Hernandez, P. Gomez-Ramos, M.A. Moran, R. Hen, and J. Avila Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice EMBO J. 20 2001 27 39 (Pubitemid 32099099)
14. C.J. Phiel, C.A. Wilson, V.M. Lee, and P.S. Klein GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides Nature 423 2003 435 439 (Pubitemid 36626994)
15. T. Engel, F. Hernandez, J. Avila, and J.J. Lucas Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3 J. Neurosci. 26 2006 5083 5090 (Pubitemid 44315289)
16. E. Rockenstein, M. Torrance, A. Adame, M. Mante, P. Bar-on, J.B. Rose, L. Crews, and E. Masliah Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation J. Neurosci. 27 2007 1981 1991
17. O. Kaidanovich-Beilin, T.V. Lipina, K. Takao, M. van Eede, S. Hattori, C. Laliberté, M. Khan, K. Okamoto, J.W. Chambers, P.J. Fletcher, K. Macaulay, B.W. Doble, M. Henkelman, T. Miyakawa, J. Roder, and J.R. Woodgett Abnormalities in brain structure and behavior in GSK-3alpha mutant mice Mol. Brain 2 2009 1 23
18. O. Kaidanovich-Beilin, A. Milman, A. Weizman, C. Pick, and H. Eldar-Finkelman Rapid anti-depressive like activity of specific GSK-3 inhibitor, and its effect on β-catenin in the mouse hippocampus Biol. Psychiatry 55 2004 781 784 (Pubitemid 38429867)
19. T.D. Gould, H. Einat, R. Bhat, and H.K. Manji AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test Int. J. Neuropsychopharmacol. 7 2004 387 390 (Pubitemid 39648068)
20. W.T. O'Brien, A.D. Harper, F. Jove, J.R. Woodgett, S. Maretto, S. Piccolo, and P.S. Klein Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium J. Neurosci. 24 2004 6791 6798 (Pubitemid 38993901)
21. A. Rosa, M. Kaster, R. Binfaré, S. Morales, E. Martín-Aparicio, M. Navarro-Rico, A. Martinez, M. Medina, A. García, M. López, and A. Rodrigues Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 1549 1556
22. T.Y. Eom, and R.S. Jope Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3alpha/beta impairs in vivo neural precursor cell proliferation Biol. Psychiatry 66 2009 494 502
23. W.Y. Kim, X. Wang, Y. Wu, B.W. Doble, S. Patel, J.R. Woodgett, and W.D. Snider GSK-3 is a master regulator of neural progenitor homeostasis Nat. Neurosci. 12 2009 1390 1397
24. F. Karege, N. Perroud, S. Burkhardt, M. Schwald, E. Ballmann, R. La Harpe, and A. Malafosse Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3beta in ventral prefrontal cortex of depressed suicide victims Biol. Psychiatry 61 2007 240 245 (Pubitemid 46072784)
25. E. Saus, V. Soria, G. Escaramis, J.M. Crespo, J. Valero, A. Gutierrez-Zotes, L. Martorell, E. Vilella, J.M. Menchon, X. Estivill, M. Gratacos, and M. Urretavizcaya A haplotype of glycogen synthase kinase 3beta is associated with early onset of unipolar major depression Genes Brain Behav. 9 2011 799 807
26. G.N. Pandey, X. Ren, H.S. Rizavi, and Y. Dwivedi Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment J. Psychiatr. Res. 44 2011 143 148
27. A. Hye, F. Kerr, N. Archer, C. Foy, M. Poppe, R. Brown, G. Hamilton, J. Powell, B. Anderton, and S. Lovestone Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease Neurosci. Lett. 373 2005 1 4 (Pubitemid 39536210)
28. O.V. Forlenza, C.A. Torres, L.L. Talib, V.J. de Paula, H.P. Joaquim, B.S. Diniz, and W.F. Gattaz Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease J. Psychiatr. Res. 45 2011 220 224
29. J.H. Hu, H. Zhang, R. Wagey, C. Krieger, and S.L. Pelech Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord J. Neurochem. 85 2003 432 442 (Pubitemid 36438338)
30. S. Lovestone, R. Killick, M. Di Forti, and R. Murray Schizophrenia as a GSK-3 dysregulation disorder Trends Neurosci. 30 2007 142 149 (Pubitemid 46482684)
31. N. Kozlovsky, R.H. Belmaker, and G. Agam GSK-3 and the neurodevelopmental hypothesis of schizophrenia Eur. Neuropsychopharmacol. 12 2002 13 25 (Pubitemid 34098826)
32. E. Beurel, S.M. Michalek, and R.S. Jope Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3) Trends Immunol. 31 2011 24 31
33. H. Wang, J. Brown, and M. Martin Glycogen synthase kinase 3: a point of convergence for the host inflammatory response Cytokine 53 2011 130 140
34. C. Parr, R. Carzaniga, S.M. Gentleman, F. Van Leuven, J. Walter, and M. Sastre Glycogen synthase kinase 3 inhibition promotes lysosomal biogenesis and autophagic degradation of the amyloid-beta precursor protein Mol. Cell. Biol. 32 2012 4410 4418
35. L. Avrahami, D. Farfara, M. Shaham-Kol, R. Vassar, D. Frenkel, and H. Eldar-Finkelman Inhibition of GSK-3 ameliorates beta-amyloid(A-beta) pathology and restores lysosomal acidification and mTOR activity in the Alzheimer's disease mouse model. In vivo and in vitro studies J. Biol. Chem. 288 2013 1295 1306
36. H. Eldar-Finkelman, and A. Martinez GSK-3 inhibitors: preclinical and clinical focus on CNS Front. Mol. Neurosci. 4 2011 32
37. S. Phukan, V.S. Babu, A. Kannoji, R. Hariharan, and V.N. Balaji GSK3beta: role in therapeutic landscape and development of modulators Br. J. Pharmacol. 160 2011 1 19
38. S.P. Davies, H. Reddy, M. Caivano, and P. Cohen Specificity and mechanism of action of some commonly used protein kinase inhibitors Biochem. J. 351 2000 95 105
39. J. Bain, L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, H. McLauchlan, I. Klevernic, J.S. Arthur, D.R. Alessi, and P. Cohen The selectivity of protein kinase inhibitors: a further update Biochem. J. 408 2007 297 315
40. K.P. Hoeflich, J. Luo, E.A. Rubie, M.S. Tsao, O. Jin, and J.R. Woodgett Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation Nature 406 2000 86 90 (Pubitemid 30460216)
41. M.A. Mines, C.J. Yuskaitis, M.K. King, E. Beurel, and R.S. Jope GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism PLoS One 5 2010 e9706
42. M.P. Soutar, W.Y. Kim, R. Williamson, M. Peggie, C.J. Hastie, H. McLauchlan, W.D. Snider, P.R. Gordon-Weeks, and C. Sutherland Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain J. Neurochem. 115 2011 974 983
43. L.T. Alon, S. Pietrokovski, S. Barkan, L. Avrahami, O. Kaidanovich-Beilin, J.R. Woodgett, A. Barnea, and H. Eldar-Finkelman Selective loss of glycogen synthase kinase-3alpha in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation FEBS Lett. 585 2011 1158 1162
44. H. Cheng, J. Woodgett, M. Maamari, and T. Force Targeting GSK-3 family members in the heart: a very sharp double-edged sword J. Mol. Cell. Cardiol. 51 2011 607 613
45. D.E. Hurtado, L. Molina-Porcel, J.C. Carroll, C. Macdonald, A.K. Aboagye, J.Q. Trojanowski, and V.M. Lee Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease J. Neurosci. 32 2011 7392 7402
46. F. Lo Monte, T. Kramer, J. Gu, U.R. Anumala, L. Marinelli, V. La Pietra, E. Novellino, B. Franco, D. Demedts, F. Van Leuven, A. Fuertes, J.M. Dominguez, B. Plotkin, H. Eldar-Finkelman, and B. Schmidt Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3alpha J. Med. Chem. 55 2011 4407 4424
47. J.R. Woodgett, and P. Cohen Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3 and casein kinase-II (glycogen synthase kinase-5) Biochim. Biophys. Acta 788 1984 339 347 (Pubitemid 14031544)
48. C.J. Fiol, J.S. Williams, C.H. Chou, Q.M. Wang, P.J. Roach, and O.M. Andrisani A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression J. Biol. Chem. 269 1994 32187 32193
49. R. Ilouz, N. Kowelsman, M. Eisenstein, and H. Eldar-Finkelman Identification of novel glycogen synthase kinase-3beta substrate-interacting residues suggests a common mechanism for substrate recognition J. Biol. Chem. 281 2006 30621 30630 (Pubitemid 44582118)
50. R. Dajani, E. Fraser, S.M. Roe, N. Young, V. Good, T.C. Dale, and L.H. Pearl Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition Cell 105 2001 721 732 (Pubitemid 32635102)
51. E. ter Haar, J.T. Coll, D.A. Austen, H.M. Hsiao, L. Swenson, and J. Jain Structure of GSK3beta reveals a primed phosphorylation mechanism Nat. Struct. Biol. 8 2001 593 596 (Pubitemid 32613006)
52. K. Hughes, E. Nicolakaki, S.E. Plyte, N.F. Totty, and J.R. Woodgett Modulation of glycogen synthase kinase-3 family by tyrosine kinase phosphorylation EMBO J. 12 1993 803 808 (Pubitemid 23073729)
53. P.A. Lochhead, R. Kinstrie, G. Sibbet, T. Rawjee, N. Morrice, and V. Cleghon A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation Mol. Cell 24 2006 627 633 (Pubitemid 350284229)
54. A. Cole, S. Frame, and P. Cohen Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event Biochem. J. 377 2004 249 255 (Pubitemid 38114452)
55. S. Frame, and P. Cohen GSK-3 takes center stage more than 20 years after its discovery Biochem. J. 359 2001 1 16 (Pubitemid 32939202)
56. R. Ilouz, S. Pietrokovsky, M. Eisenstein, and H. Eldar-Finkelman New insights into the autoinhibition mechanism of glycogen synthase kinase-3 beta J. Mol. Biol. 385 2008 999 1007
57. B. Plotkin, O. Kaidanovich, I. Talior, and H. Eldar-Finkelman Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3 J. Pharmacol. Exp. Ther. 2003 974 980 (Pubitemid 36621426)
58. S. Frame, P. Cohen, and R.M. Biondi A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation, Mo.l Cell 7 2001 1321 1327 (Pubitemid 32607364)
59. O. Kaidanovich-Beilin, and H. Eldar-Finkelman Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle J. Pharmacol. Exp. Ther. 316 2006 17 24 (Pubitemid 41832576)
60. G. Chen, K.A. Bower, C. Ma, S. Fang, C.J. Thiele, and J. Luo Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death FASEB J. 18 2004 1162 1164 (Pubitemid 39561557)
61. E.S. Chung, E. Bok, S. Sohn, Y.D. Lee, H.H. Baik, and B.K. Jin GT1b-induced neurotoxicity is mediated by the Akt/GSK-3/tau signaling pathway but not caspase-3 in mesencephalic dopaminergic neurons BMC Neurosci. 11 2011 74
62. M. Shapira, A. Licht, A. Milman, C.G. Pick, E. Shohami, and H. Eldar-Finkelman Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury Mol. Cell. Neurosci. 34 2007 571 577 (Pubitemid 46483079)
63. H.J. Kim, and S.A. Thayer Lithium increases synapse formation between hippocampal neurons by depleting phosphoinositides Mol. Pharmacol. 75 2009 1021 1030
64. A. Licht-Murava, B. Plotkin, M. Eisenstein, and H. Eldar-Finkelman Elucidating substrate and inhibitor binding sites on the surface of GSK-3beta and the refinement of a competitive inhibitor J. Mol. Biol. 408 2011 366 378
65. A. Ben-Shimon, and M. Eisenstein Computational mapping of anchoring spots on protein surfaces J. Mol. Biol. 402 2010 259 277
66. T. Engel, P. Goni-Oliver, J.J. Lucas, J. Avila, and F. Hernandez Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert J. Neurochem. 99 2006 1445 1455 (Pubitemid 44924224)
67. G.V. De Ferrari, M.A. Chacon, M.I. Barria, J.L. Garrido, J.A. Godoy, G. Olivares, A.E. Reyes, A. Alvarez, M. Bronfman, and N.C. Inestrosa Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils Mol. Psychiatry 8 2003 195 208 (Pubitemid 36315228)
68. H. Nakashima, T. Ishihara, P. Suguimoto, O. Yokota, E. Oshima, A. Kugo, S. Terada, T. Hamamura, J.Q. Trojanowski, V.M. Lee, and S. Kuroda Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies Acta Neuropathol. 110 2005 547 556 (Pubitemid 41763984)
69. A. Caccamo, S. Oddo, L.X. Tran, and F.M. LaFerla Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles Am. J. Pathol. 170 2007 1669 1675 (Pubitemid 47339311)
70. E.M. Toledo, N.C. Inestrosa, Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease, Mol. Psychiatry 15 (2010) 272-285, 228.
71. W. Noble, E. Planel, C. Zehr, V. Olm, J. Meyerson, F. Suleman, K. Gaynor, L. Wang, J. LaFrancois, B. Feinstein, M. Burns, P. Krishnamurthy, Y. Wen, R. Bhat, J. Lewis, D. Dickson, and K. Duff Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo Proc. Natl. Acad. Sci. U. S. A. 102 2005 6990 6995 (Pubitemid 40675429)
72. K. Watase, J.R. Gatchel, Y. Sun, E. Emamian, R. Atkinson, R. Richman, H. Mizusawa, H.T. Orr, C. Shaw, and H.Y. Zoghbi Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model PLoS Med. 4 2007 e182
73. M.L. Selenica, H.S. Jensen, A.K. Larsen, M.L. Pedersen, L. Helboe, M. Leist, and J. Lotharius Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation Br. J. Pharmacol. 152 2007 959 979 (Pubitemid 350100498)
74. A. Al-Chalabi, P.J. Shaw, C.A. Young, K.E. Morrison, C. Murphy, M. Thornhill, J. Kelly, I.N. Steen, and P.N. Leigh Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31] BMC Neurol. 11 2011 111
75. S.H. Koh, Y. Kim, H.Y. Kim, S. Hwang, C.H. Lee, and S.H. Kim Inhibition of glycogen synthase kinase-3 suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS Exp. Neurol. 205 2007 336 346 (Pubitemid 46755762)
76. H.L. Feng, Y. Leng, C.H. Ma, J. Zhang, M. Ren, and D.M. Chuang Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model Neuroscience 155 2008 567 572
77. J.A. Mohawk, M. Miranda-Anaya, O. Tataroglu, and M. Menaker Lithium and genetic inhibition of GSK3beta enhance the effect of methamphetamine on circadian rhythms in the mouse Behav. Pharmacol. 20 2009 174 183
78. A.P. Kozikowski, H. Gunosewoyo, S. Guo, I.N. Gaisina, R.L. Walter, A. Ketcherside, C.A. McClung, A.D. Mesecar, and B. Caldarone Identification of a glycogen synthase kinase-3beta inhibitor that attenuates hyperactivity in CLOCK mutant mice ChemMedChem 6 2011 1593 1602
79. A. Avignon, K. Yamada, X. Zhou, B. Spencer, O. Cardona, S. Saba-Siddique, L. Galloway, M.L. Standaert, and R.V. Farese Chronic activation of protein kinase C in soleus muscles and other tissues of insulin-resistant type II diabetic Goto-Kakizaki (GK), obese/aged, and obese/Zucker rats. A mechanism for inhibiting glycogen synthesis Diabetes 45 1996 1396 1404 (Pubitemid 26332904)
80. Q. Li, H. Li, K. Roughton, X. Wang, G. Kroemer, K. Blomgren, and C. Zhu Lithium reduces apoptosis and autophagy after neonatal hypoxia-ischemia Cell Death Dis. 1 2010 e56
81. S. Kelly, H. Zhao, G. Hua Sun, D. Cheng, Y. Qiao, J. Luo, K. Martin, G.K. Steinberg, S.D. Harrison, and M.A. Yenari Glycogen synthase kinase 3beta inhibitor Chir025 reduces neuronal death resulting from oxygen-glucose deprivation, glutamate excitotoxicity, and cerebral ischemia Exp. Neurol. 188 2004 378 386 (Pubitemid 38891598)
82. C.L. Busceti, F. Biagioni, E. Aronica, B. Riozzi, M. Storto, G. Battaglia, F.S. Giorgi, R. Gradini, F. Fornai, A. Caricasole, F. Nicoletti, and V. Bruno Induction of the Wnt inhibitor, Dickkopf-1, is associated with neurodegeneration related to temporal lobe epilepsy Epilepsia 48 2007 694 705 (Pubitemid 46587610)
83. W.W. Min, C.J. Yuskaitis, Q. Yan, C. Sikorski, S. Chen, R.S. Jope, and R.P. Bauchwitz Elevated glycogen synthase kinase-3 activity in fragile X mice: key metabolic regulator with evidence for treatment potential Neuropharmacology 56 2009 463 472
84. M.A. Mines, and R.S. Jope Glycogen synthase kinase-3: a promising therapeutic target for fragile X syndrome Front. Mol. Neurosci. 4 2010 35
85. W. Guo, A.C. Murthy, L. Zhang, E.B. Johnson, E.G. Schaller, A.M. Allan, and X. Zhao Inhibition of GSK3beta improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome Hum. Mol. Genet. 21 2012 681 691
86. N.I. Wood, and A.J. Morton Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation Brain Res. Bull. 61 2003 375 383 (Pubitemid 36945468)
87. S. Sarkar, G. Krishna, S. Imarisio, S. Saiki, C.J. O'Kane, and D.C. Rubinsztein A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin Hum. Mol. Genet. 17 2008 170 178
88. L. Mazzardo-Martins, D.F. Martins, J. Stramosk, F.J. Cidral-Filho, A.R. Santos, Glycogen synthase kinase 3-specific inhibitor AR-A014418 decreases neuropathic pain in mice: Evidence for the mechanisms of action, Neuroscience 226 (2012) 411-420.
89. J. Zhong, X. Yang, W. Yao, and W. Lee Lithium protects ethanol-induced neuronal apoptosis Biochem. Biophys. Res. Commun. 350 2006 905 910 (Pubitemid 44596222)
90. Y. Mao, X. Ge, C.L. Frank, J.M. Madison, A.N. Koehler, M.K. Doud, C. Tassa, E.M. Berry, T. Soda, K.K. Singh, T. Biechele, T.L. Petryshen, R.T. Moon, S.J. Haggarty, and L.H. Tsai Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling Cell 136 2009 1017 1031
91. N.R. Makhortova, M. Hayhurst, A. Cerqueira, A.D. Sinor-Anderson, W.N. Zhao, P.W. Heiser, A.C. Arvanites, L.S. Davidow, Z.O. Waldon, J.A. Steen, K. Lam, H.D. Ngo, and L.L. Rubin A screen for regulators of survival of motor neuron protein levels Nat. Chem. Biol. 7 2011 544 552